Cancer Australia Research Grants
The Leukaemia Foundation is a funding partner of Cancer Australia (CA) – an Australian Government agency that provides grants through its Priority-driven Collaborative Cancer Research Scheme (PdCCRS).
This partnership ensures research supported by the Leukaemia Foundation is high quality and all Australian researchers have the opportunity to apply and receive Leukaemia Foundation research funding.
The PdCCRS funds projects in areas where research priority has been identified by CA and its funding partners.
As a funding partner, the Leukaemia Foundation sets its own research priorities and the categories to be funded in each funding round.
Recent Leukaemia Foundation qualitative research identified the need for ‘early career researchers’ to have access to funding opportunities. These are emerging academics who have been awarded a doctoral degree or other postgraduate qualification in the last five years.
Nurturing ‘early career’ medical researchers is critical to discovering better and safer blood cancer treatments and keeping the most promising and exciting talent in Australia.
Our research investment supports post-doctoral researchers with 1-3 years post-doctoral experience or post-MBBS qualifications; and post-doctoral researchers with 4-7 years post-doctoral experience or post-MBBS qualifications.
2018/19 research funding
Total funding for these CA research grants in 2018/19 is $800,000. The five projects to benefit from this funding are:
Kate Vandyke – South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia
Project title: Increasing drug delivery and improving the quality of life for multiple myeloma patients.
Laura Bray – Queensland University of Technology, Institute of Health and Biomedical Innovation
Project title: Development of a translational bioengineered microenvironment model to advance pre-clinical acute myeloid leukaemia research
Michelle Henderson – Children’s Cancer Institute, Sydney, New South Wales
Project title: Targeting the NAD pathway as a new therapeutic strategy for high-risk leukaemia in children
Jenny Wang – Children’s Cancer Institute, Sydney, New South Wales
Project title: Therapeutic targeting of a novel self-renewal signalling in leukaemia stem cells
Gabriela Brumatti – Walter and Eliza Hall Institute, Melbourne, Victoria
Project title: Targeting multidrug resistance protein 1 (MDR1) enhances the efficacy of Smac-mimetic-based therapy in acute myeloid leukaemia.
CA uses the National Health and Medical Research Council (NH&MRC) research grants management system.
Applications for grants go through two rounds of assessment:
- Grants assessed and ranked according to the NH&MRC grants peer review process.
- Applications assessed by CA against outcomes and impact, translatability, collaborations, and consumer involvement.
The CA partnership also provides an opportunity for funds gifted to the Leukaemia Foundation for disease-specific research, be directed towards high quality research, and for grants to be co-funded with CA.
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.